{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT03696485",
      "OrgStudyIdInfo": {
        "OrgStudyId": "SPMS-SCM-010"
      },
      "Organization": {
        "OrgFullName": "Stem Cell Medicine Ltd.",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "Study to Assess the Safety and Efficacy of an IT Administration of SCM-010 in SPMS",
      "OfficialTitle": "A Prospective, Single Center, Open Label, Dose Escalation Phase I/IIa Study to Assess the Safety and Efficacy of an Intrathecal Administration of SCM-010 in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)"
    },
    "StatusModule": {
      "StatusVerifiedDate": "October 2018",
      "OverallStatus": "Unknown status",
      "LastKnownStatus": "Not yet recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "February 1, 2019",
        "StartDateType": "Anticipated"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "February 1, 2021",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "February 1, 2021",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "September 30, 2018",
      "StudyFirstSubmitQCDate": "October 3, 2018",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "October 4, 2018",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "October 14, 2018",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "October 17, 2018",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Stem Cell Medicine Ltd.",
        "LeadSponsorClass": "INDUSTRY"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "Prospective, single center, open label, phase I/IIa escalating dose study. To evaluate the safety and efficacy of escalating doses of SCM-010 in subjects with SPMS.",
      "DetailedDescription": "Twelve (12) SPMS subjects will be enrolled in this study in two dose cohorts. Each subject will receive SCM- 010 by intrathecal (IT) administration at baseline and will be followed up for 24 weeks for efficacy and 48 weeks for safety."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Secondary Progressive Multiple Sclerosis (SPMS)"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Secondary Progressive Multiple Sclerosis (SPMS), safety"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Non-Randomized",
        "DesignInterventionModel": "Sequential Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "12",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "group 1: low dose",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "One intrathecal (IT) administration of SCM-010 at baseline visit",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: SCM-010"
              ]
            }
          },
          {
            "ArmGroupLabel": "group 2: high dose",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "One intrathecal (IT) administration of SCM-010 at baseline visit",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: SCM-010"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "SCM-010",
            "InterventionDescription": "SCM-010 is comprised of adipose derived expanded mesenchymal cells (ADSC), suspended in Plasma-Lyte and intended for intrathecal (IT) administration.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "group 1: low dose",
                "group 2: high dose"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Adverse Events (AEs) reported during the trial",
            "PrimaryOutcomeDescription": "Safety data will be collected following the one IT administration of SCM-010 at baseline visit",
            "PrimaryOutcomeTimeFrame": "48 weeks"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Change in MRI scans from baseline",
            "SecondaryOutcomeDescription": "Changes in lesions from baseline MRI scan.",
            "SecondaryOutcomeTimeFrame": "24 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Change from baseline in EDSS score",
            "SecondaryOutcomeDescription": "The Expanded Disability Status Scale (EDSS) will be measured during the study. range of the scale 0-10",
            "SecondaryOutcomeTimeFrame": "24 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Time to Confirmed Disease Progression (CDP)",
            "SecondaryOutcomeDescription": "CDP for an individual subject is defined as at least 3-months confirmed EDSS increase from baseline.\n\nThe Expanded Disability Status Scale (EDSS) will be measured during the study. range of the scale 0-10",
            "SecondaryOutcomeTimeFrame": "24 weeks"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nMale or female subjects (18-60 years of age) diagnosed with SPMS.\nSPMS defined as relapsing-remitting disease followed by progression of disability independent of or not explained by multiple sclerosis (MS) relapses for at least 2 years.\nSubjects should be ambulatory with an EDSS score of 3-6.5 (inclusive) at screening and baseline visits.\nSubjects should be able to go through a lipoaspiration procedure, evaluated by the study's plastic surgeon.\nWomen capable of child bearing must have a negative urine pregnancy test at screening and baseline visits.\nSubjects must use an adequate contraceptive method throughout the study.\nCoagulation tests including INR, PTT and prothrombin time (PT) within normal range.\nSubjects must be willing and able to comply with the protocol requirements for the duration of the study.\nAbility to provide written informed consent.\n\nExclusion Criteria:\n\nRelapsing remitting multiple sclerosis (RRMS) or primary progressive multiple sclerosis (PPMS) as defined by the revised McDonald criteria.\nAny chronic central nervous system (CNS) disease other than SPMS.\nClinical relapse within 3 months prior to study entry.\nSubjects diagnosed with any systemic autoimmune disease.\nContraindications or inability to undergo lumbar puncture (LP) procedure and or intrathecal administration.\nSevere anemia (hemoglobin < 10 g/dL).\nAbnormal renal function (serum creatinine more than 1.5xULN or creatinine clearance <30 ml/min).\nTested positive for HIV, hepatitis (HBV and HCV).\nKnown as positive for VDRL and/or tuberculosis.\nActive malignant disease of any kind. However, a patient, who has had a malignant disease in the past, was treated and is currently disease - free for at least 7 years, may be considered eligible. In this case the sponsor medical expert approval is required.\nPrevious cell therapy treatment.\nPrevious total body irradiation or total lymphoid irradiation.\nPrevious use of natalizumab or any anti-B cell agent within 6 months prior to screening.\nPrevious use of immunosuppressant including Mitoxantrone, Alemtuzumab, Cladribine or any other cytotoxic agent.\nPrevious use of Fingolimod or Dimethyl Fumarate within 2 months prior to screening. Subjects who were treated with any of these medications will be excluded if they do not have a lymphocyte count within normal range at screening.\nPrevious use of Teriflunomide within 12 months if no accelerated elimination procedure was used.\nPrevious treatment with immunomodulators (including IFNÎ² 1a and 1b, and IV Immunoglobulin (IVIG) or Glatiramer Acetate (GA) within 2 months prior to screening.\nA known history of sensitivity to aminoglycosides and or to Vancomycin.\nA known history of sensitivity to Gadolinium.\nInability to successfully undergo MRI scanning.\nTreatment with any kind of steroids or ACTH during the last 30 days prior to screening.\nSubjects with clotting disorders or receiving treatment with anticoagulants.\nAny relevant medical, surgical, or psychiatric condition, laboratory value, or concomitant medication which, in the opinion of the Principle Investigator, makes the subject unsuitable for study entry or potentially unable to complete all aspects of the study.\nSubjects with BMI < 20.\nPregnant or breast-feeding women.\nKnown or suspected drug or alcohol abuse.\nParticipation in any investigational drug study within 6 months prior to screening.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "60 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Arnon Karni, Dr.",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "+972-36974380",
            "CentralContactEMail": "arnonk@tlvmc.gov.il"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Arnon Karni, Dr.",
            "OverallOfficialAffiliation": "Tel Aviv Medical Center",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Tel Aviv Medical Center",
            "LocationCity": "Tel Aviv",
            "LocationCountry": "Israel"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000009362",
            "ConditionMeshTerm": "Neoplasm Metastasis"
          },
          {
            "ConditionMeshId": "D000009103",
            "ConditionMeshTerm": "Multiple Sclerosis"
          },
          {
            "ConditionMeshId": "D000020528",
            "ConditionMeshTerm": "Multiple Sclerosis, Chronic Progressive"
          },
          {
            "ConditionMeshId": "D000012598",
            "ConditionMeshTerm": "Sclerosis"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          },
          {
            "ConditionAncestorId": "D000020278",
            "ConditionAncestorTerm": "Demyelinating Autoimmune Diseases, CNS"
          },
          {
            "ConditionAncestorId": "D000020274",
            "ConditionAncestorTerm": "Autoimmune Diseases of the Nervous System"
          },
          {
            "ConditionAncestorId": "D000009422",
            "ConditionAncestorTerm": "Nervous System Diseases"
          },
          {
            "ConditionAncestorId": "D000003711",
            "ConditionAncestorTerm": "Demyelinating Diseases"
          },
          {
            "ConditionAncestorId": "D000001327",
            "ConditionAncestorTerm": "Autoimmune Diseases"
          },
          {
            "ConditionAncestorId": "D000007154",
            "ConditionAncestorTerm": "Immune System Diseases"
          },
          {
            "ConditionAncestorId": "D000009385",
            "ConditionAncestorTerm": "Neoplastic Processes"
          },
          {
            "ConditionAncestorId": "D000009369",
            "ConditionAncestorTerm": "Neoplasms"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M11212",
            "ConditionBrowseLeafName": "Multiple Sclerosis",
            "ConditionBrowseLeafAsFound": "Multiple Sclerosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M14567",
            "ConditionBrowseLeafName": "Sclerosis",
            "ConditionBrowseLeafAsFound": "Sclerosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M11459",
            "ConditionBrowseLeafName": "Neoplasm Metastasis",
            "ConditionBrowseLeafAsFound": "Secondary",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M21466",
            "ConditionBrowseLeafName": "Multiple Sclerosis, Chronic Progressive",
            "ConditionBrowseLeafAsFound": "Secondary Progressive Multiple Sclerosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M3781",
            "ConditionBrowseLeafName": "Autoimmune Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M21251",
            "ConditionBrowseLeafName": "Demyelinating Autoimmune Diseases, CNS",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M21247",
            "ConditionBrowseLeafName": "Autoimmune Diseases of the Nervous System",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M6061",
            "ConditionBrowseLeafName": "Demyelinating Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9352",
            "ConditionBrowseLeafName": "Immune System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11482",
            "ConditionBrowseLeafName": "Neoplastic Processes",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC10",
            "ConditionBrowseBranchName": "Nervous System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC20",
            "ConditionBrowseBranchName": "Immune System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC04",
            "ConditionBrowseBranchName": "Neoplasms"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M85407",
            "InterventionBrowseLeafName": "Plasma-lyte 148",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "PhSol",
            "InterventionBrowseBranchName": "Pharmaceutical Solutions"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}